Cabergoline tablets (500 microgram, 1mg, 2mg)have been added to the formulary as an amber (specialist input) option for the management of hyperprolactinaemic disorders. Click here for more information.
Cholurso® 250mg tablets have been removed as the preferred brand of ursodeoxycholic acid; generic prescribing is now recommended. Click here for more information.
Dexamfetamine sulfate tablets 5mg have been added to the formulary as an amber (specialist input) option for the treatment of narcolepsy in adults. Click here for more information.
Kyleena® 19.5mg(levonorgestrel) intrauterine systemhas been added to formulary as a green (first line) option for contraception in women, licensed for up to 5 years. Click here for more information.
Emollients: The choice of formulary emollient preparations has been updated with supporting guidance to aid prescribers. Click here for more information.
Anal irrigation systems: Following the inclusion of the new guidance published in August 2018, a specific list of locally agreed products has been added to the guidance reflecting current local practice. Please see the formulary for further guidance.
Anal inserts: Guidance has updated and added to the formulary to offer advice and support to GPs, alongside the list of locally agreed products. Please see the formulary for further guidance.
October 2018
Ulipristal acetate (Esmya) 5mg tablets have been reclassified as red (hospital only) following an EMA safety review. Click here for more information.
Adult asthma: NICE NG80: Asthma: diagnosis, monitoring and chronic asthma management (November 2017), prompted a review of the current guidance, which is based on recommendations made by the British Throacic Society (BTS) and the Scottish Intercollegiate Guideline Network (SIGN). Formulary guidance continues to follow the recommendations made by BTS/SIGN, with minor changes to offer clarity to existing guidance and relevant product choices. Please see the formulary for further guidance.
Management of pain and opioids: Acute and chronic non-malignant painguidance, with consideration to the Opioids Aware resource hosted by the Faculty of Pain Medicine, has been added in the formulary. Please see the formulary for further guidance.
Commissioning Policy: The
routine commissioning of Tresiba® (insulin degludec)
is accepted in Devon for the treatment of patients with type 1
diabetes who meet specific criteria (See
Commissioning Policy for more information)
Commissioning Policy: The
routine commissioning of Tresiba® (insulin degludec) in Devon for the
treatment of type 2 diabetes is
unchanged and is
not accepted (See Commissioning Policy for more information)
Commissioning Policy: The
routine commissioning of Trelegy® Ellipta® (combination of fluticasone furoate,
umeclidinium bromide, and vilanterol trifenatate)
is accepted in Devon for maintenance treatment in adult patients
with moderate to severe chronic obstructive pulmonary disease (COPD) (See
Commissioning Policy for more details)
August 2018
AntiStatic Space Chamber Plus (medium-volume spacer device) standard and compact devices have been added into the formulary here to provide an antistatic spacer option at a lower acquisition cost than current formulary products
Octenisan wash mitts have been added into the formulary here for antiseptic bedside washing of lower limbs of patients with chronic ulceration
Pizotifen tablets 500microgram and 1.5mg have been removed from the formulary; the use of pizotifen as a prophylactic option for migraine in adults has been superseded. Patients that are already established on pizotifen and find it effective can continue to use it.
Darbepoetin alfa has been reclassified as red; prescribing and monitoring is by secondary care only. Previous shared care documents have been archived, and are available for reference only (here). See formulary entry here.
Anal irrigation systems: Brief guidance has been added to support GPs who may be asked to prescribe these appliances following recommendation from the NHS Bladder and Bowel Care team. Click here for more information.
Acute sinusitis: Following publication of NICE NG79: Sinusitis (acute): antimicrobial prescribing (October 2017), formulary guidance has been revised and updated. The guidance can be found here
Acute sore throat: Following publication of NICE NG84: Sore throat (acute): antimicrobial prescribing (January 2018), formulary guidance has been revised and updated. The guidance can be found here
Management of migraine: The formulary guidance has been reviewed and updated in line with NICE CG150: headaches in over 12s: diagnosis and management (updated November 2015). The guidance can be found here
Oral nutritional supplements: Following consultation with local dietitian specialists in North and East Devon, the choices of formulary oral nutritional supplements have been reviewed. Formulary recommended products can be found here
Parkinson's disease management: The formulary guidance has been reviewed and updated in line with NICE NG71: Parkinson's disease in adults (July 2017). Dopaminergic drugs used in Parkinson's disease have been reclassified as amber (specialist input). Click here for more information.
Vitamin and mineral supplementation following bariatric surgery: New formulary guidance has been added to the formulary to offer support to prescribers on the nutritional supplementation for patients who have undergone bariatric surgery. The guidance can be found here.
Following public consultation; NHS England and NHS Clinical Commissioners published guidance for CCGs on items which should not be routinely prescribed in primary care. Click here for more information. The following items have new guidance attached in the formulary:
